These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 32951896)
1. mRNA expression in low grade serous ovarian cancer: Results of a nanoString assay in a diverse population. Jordan SE; Saad H; Covarrubias AS; Siemon J; Pearson JM; Slomovitz BM; Huang M; Pinto A; Schlumbrecht M; George SH Gynecol Oncol; 2020 Nov; 159(2):554-562. PubMed ID: 32951896 [TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma. Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420 [TBL] [Abstract][Full Text] [Related]
3. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. Tsang YT; Deavers MT; Sun CC; Kwan SY; Kuo E; Malpica A; Mok SC; Gershenson DM; Wong KK J Pathol; 2013 Dec; 231(4):449-56. PubMed ID: 24549645 [TBL] [Abstract][Full Text] [Related]
4. Molecular characterization of 103 ovarian serous and mucinous tumors. Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228 [TBL] [Abstract][Full Text] [Related]
5. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy. Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350 [TBL] [Abstract][Full Text] [Related]
6. Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer. Van Nieuwenhuysen E; Busschaert P; Laenen A; Moerman P; Han SN; Neven P; Lambrechts D; Vergote I Neoplasia; 2019 Jun; 21(6):582-590. PubMed ID: 31054497 [TBL] [Abstract][Full Text] [Related]
7. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors. Wong KK; Bateman NW; Ng CW; Tsang YTM; Sun CS; Celestino J; Nguyen TV; Malpica A; Hillman RT; Zhang J; Futreal PA; Rojas C; Conrads KA; Hood BL; Dalgard CL; Wilkerson MD; Phippen NT; Conrads TP; Maxwell GL; Sood AK; Gershenson DM J Transl Med; 2022 Dec; 20(1):606. PubMed ID: 36528667 [TBL] [Abstract][Full Text] [Related]
8. Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability. Shrestha R; Llaurado Fernandez M; Dawson A; Hoenisch J; Volik S; Lin YY; Anderson S; Kim H; Haegert AM; Colborne S; Wong NKY; McConeghy B; Bell RH; Brahmbhatt S; Lee CH; DiMattia GE; Le Bihan S; Morin GB; Collins CC; Carey MS Cancer Res; 2021 Apr; 81(7):1681-1694. PubMed ID: 33441310 [TBL] [Abstract][Full Text] [Related]
9. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas. Tone AA; McConechy MK; Yang W; Ding J; Yip S; Kong E; Wong KK; Gershenson DM; Mackay H; Shah S; Gilks B; Tinker AV; Clarke B; McAlpine JN; Huntsman D BMC Cancer; 2014 Dec; 14():982. PubMed ID: 25523272 [TBL] [Abstract][Full Text] [Related]
10. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver. Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A; Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818 [TBL] [Abstract][Full Text] [Related]
12. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232 [TBL] [Abstract][Full Text] [Related]
13. Low frequency of BRAF and KRAS mutations in Chinese patients with low-grade serous carcinoma of the ovary. Xu Y; Bi R; Xiao Y; Tu X; Li M; Li A; Shan L; Zhou S; Yang W Diagn Pathol; 2017 Dec; 12(1):87. PubMed ID: 29273082 [TBL] [Abstract][Full Text] [Related]
14. Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer. Weberpals JI; Pugh TJ; Marco-Casanova P; Goss GD; Andrews Wright N; Rath P; Torchia J; Fortuna A; Jones GN; Roudier MP; Bernard L; Lo B; Torti D; Leon A; Marsh K; Hodgson D; Duciaume M; Howat WJ; Lukashchuk N; Lazic SE; Whelan D; Sekhon HS Cancer Med; 2021 May; 10(9):3045-3058. PubMed ID: 33811746 [TBL] [Abstract][Full Text] [Related]
15. Genetic alteration and immunohistochemical staining patterns of ovarian high-grade serous adenocarcinoma with special emphasis on p53 immnnostaining pattern. Lee SH; Kim H; Kim WY; Han HS; Lim SD; Kim WS; Kim S; Hwang TS Pathol Int; 2013 May; 63(5):252-9. PubMed ID: 23714252 [TBL] [Abstract][Full Text] [Related]
16. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Wong KK; Tsang YT; Deavers MT; Mok SC; Zu Z; Sun C; Malpica A; Wolf JK; Lu KH; Gershenson DM Am J Pathol; 2010 Oct; 177(4):1611-7. PubMed ID: 20802181 [TBL] [Abstract][Full Text] [Related]